SCYNEXIS INC (SCYX) stock intrinsic value fair value estimate & owner earnings analysis

SCYNEXIS is a biopharmaceutical company built around ibrexafungerp, a novel antifungal it discovered and won FDA approval for as BREXAFEMME, used to treat and prevent recurrent vaginal yeast infections. The business has changed shape twice in the last few years, and both changes matter a great deal to what the shares are worth today. The first change: SCYNEXIS originally tried to sell BREXAFEMME itself, building a sales organization in 2021-2022 that cost far more than the drug ever brought in. In 2023 the company recalled the product, wound the sales force down, and instead licensed the drug's commercialization rights worldwide (outside the U.S. under one deal, and separately for Greater China) to two larger partners: GSK for most of the world, and Hansoh for mainland China, Hong Kong, Macau and Taiwan. GSK paid a $90 million upfront fee plus a $25 million milestone in 2023 for those rights. The second change came in November 2025, when SCYNEXIS transferred the U.S. drug application itself to GSK, ending its own role in commercializing the product anywhere. GSK now controls the drug everywhere, has said it intends to begin talking to the FDA in 2026 about relaunching BREXAFEMME in the U.S., but has not yet done so, and has not set a firm date. Separately, GSK and SCYNEXIS recently agreed to stop a large clinical study (MARIO, testing the drug in a hospital-acquired infection) that GSK no longer wanted to fund, in exchange for a one-time $24.8 million payment to SCYNEXIS. What's left at SCYNEXIS today is a lean research organization spending on one early-stage pipeline compound (SCY-247, still in an early safety study with a mid-stage study planned), a set of contractual rights to future payments from GSK (up to $49 million if U.S. regulatory approval for the relaunch is achieved, up to $57.5 million more tied to early commercial milestones, and further payments tied to sales if the relaunch is a large success) and from Hansoh (which just received Chinese regulatory approval for the drug and owes SCYNEXIS a commercialization milestone plus roughly 10% royalties on its China sales once it launches), and about $56 million of cash and investments on the balance sheet with no debt. The core problem for valuing this business is that its own running costs - roughly $35-40 million a year of research and administrative spending - are large relative to what the remaining licensed-out assets can realistically be expected to generate. BREXAFEMME was never a strong seller even when SCYNEXIS was actively pushing it, and the milestone payments, while real and contractually specified, are one-time events, not a recurring revenue stream, unless and until real product sales resume. That gap between spending and realistic incoming cash is the central fact driving every case below. In the case where GSK's relaunch plans stall or fail, Hansoh's China launch disappoints, and the pipeline compound doesn't pan out, the company continues spending at something like its current pace until cash runs low, at which point - consistent with what the company has told investors it would do - it would need to scale back research sharply to conserve cash. On that path, the roughly $56 million of cash gets spent down without being replaced by much new income, and the shares are worth modestly less than the cash on hand today, once spent down to that point: around $(0.70) per share. In the middle, more likely case, the Chinese royalty stream (already de-risked by the approval Hansoh has in hand) begins contributing a few million dollars a year within a couple of years, and there's a reasonable, though far from certain, chance that GSK's stated 2026 plan to re-engage the FDA eventually produces at least the regulatory milestone payment later in the decade. Spending is trimmed once cash gets tight, as the company has said it would do. Even with these credits, the company's own overhead is large enough relative to this income that the shares are worth only modestly less than today's cash pile, around $(0.30) per share. In the favorable case, GSK follows through on its stated plan, wins U.S. regulatory clearance for the relaunch, and successfully reintroduces BREXAFEMME with its much larger commercial organization, triggering both the regulatory and initial commercial milestones and eventually a meaningful (if not enormous, given the product's modest sales history) ongoing royalty; Hansoh's China launch also succeeds at a reasonable scale. Even here, the milestone payments and eventual royalties only modestly exceed what the company will spend getting there and afterward, putting the shares at around $0.45 per share. We have not given the earlystage pipeline compound any value in any of these cases - it is too early in testing to know if it will work, and a share price built on hope for it would not be a valuation, it would be a guess. A reader may notice SCYNEXIS's stock has recently traded under $1 and drawn a Nasdaq notice about the minimum share price requirement; the company has said it intends to fix this, if needed, with a reverse stock split, and remains in compliance with every other listing requirement, so we don't see this by itself as pointing toward the company leaving the exchange. We also don't see anything in the recent filings suggesting the company can't fund its operations for the next year - it says explicitly that it can - though it has also said plainly that if it can't raise more money on acceptable terms down the road, it would need to delay or scale back its research, which is exactly what the less favorable cases above assume happens. Given how tightly bunched and generally unattractive these outcomes are - even the favorable case is only modestly positive - the margin-of-safety price is very low, and it applies only once there is real evidence that the favorable case is starting to play out: specifically, GSK actually beginning its promised FDA discussions, or Hansoh actually beginning to sell the drug in China. Absent that confirmation, the estimated value offers no margin of safety.